Literature DB >> 12106513

The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing.

William E Lafferty1.   

Abstract

An increased prevalence of genital herpes simplex virus (HSV) infection has been documented worldwide. In the USA, the National Health and Nutrition Examination Survey (NHANES), conducted from 1988 to 1994, revealed the seroprevalence of HSV-2 in persons 12 years of age or older to be 21.9%, an increase of 30% in age-adjusted seroprevalence of HSV-2 since the previous survey that was conducted from 1976 to 1980. Several European studies have documented a high prevalence of HSV-2 in antenatal populations. The advent of highly sensitive virological tests has confirmed that HSV-2 is the most common cause of genital ulceration in the developing world. People with a high standard of living may escape oral HSV-1 infection in childhood. Since asymptomatic oral shedding of HSV-1 is common, adults without immunity to HSV-1 who practise oral sex are especially at risk for genital HSV-1 infection. In some European cohorts, HSV-1 has been a more common aetiological agent of primary genital herpes than HSV-2. These patient groups may benefit from the use of HSV-1 in addition to HSV-2 type-specific serology.

Entities:  

Mesh:

Year:  2002        PMID: 12106513

Source DB:  PubMed          Journal:  Herpes        ISSN: 0969-7667


  12 in total

1.  Performance of two commercial enzyme-linked immunosorbent assay kits using recombinant glycoprotein G2 antigen for detection of herpes simplex virus type 2 specific antibodies.

Authors:  Sharmila M Reddy; P Balakrishnan; S Uma; S P Thyagarajan; Suniti Solomon
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

Review 2.  Diagnostics for herpes simplex virus: is PCR the new gold standard?

Authors:  Lara B Strick; Anna Wald
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 3.  Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy.

Authors:  Chris L McGowin; Richard B Pyles
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

4.  Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.

Authors:  Kiyomitsu Katsumata; Adriana Weinberg; Koji Chono; Shoji Takakura; Toru Kontani; Hiroshi Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

Review 5.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  The diagnosis of genital herpes - beyond culture: An evidence-based guide for the utilization of polymerase chain reaction and herpes simplex virus type-specific serology.

Authors:  S Ratnam; A Severini; G Zahariadis; M Petric; B Romanowski
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-07       Impact factor: 2.471

Review 7.  Vertical transmission of genital herpes: prevention and treatment options.

Authors:  Cheryl A Jones
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects.

Authors:  Min Kim; Janette Taylor; John Sidney; Zorka Mikloska; Neil Bodsworth; Katerina Lagios; Heather Dunckley; Karen Byth-Wilson; Martine Denis; Robert Finlayson; Rajiv Khanna; Alessandro Sette; Anthony L Cunningham
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa.

Authors:  Melissa M Linehan; Susan Richman; Claude Krummenacher; Roselyn J Eisenberg; Gary H Cohen; Akiko Iwasaki
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 10.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.